Ovarian cancer is currently treated with traditional chemotherapeutics, which are not very efficient, and the anti-tumor drug sensitivity prediction can effectively improve the quality of life or life.
Now in vitro drug screening, and patient-derived xenograft (PDX) models have been applied to predict the susceptibility of anti-tumor drugs.
In this study, the researchers found that BAK/MCL1 complex in tumor cells can predict the sensitivity of paclitaxel, MCL1 inhibitors, and their combination. Further studies on PDX models and animal experiments also illustrate the predictive effect of the BAK/MCL1 complex.
Source: Medindia
